"The scrutiny that was attributed to other companies' results is not being attributed to Wyeth's quarter in our view, " says Robert Hazlett of SunTrust Robertson Humphrey.

FORBES: Is Wyeth Getting An Easy Pass?

"It's early days, but Merck is taking the long view, " says Robert Hazlett, an analyst at SunTrust Robinson Humphrey, who has a "buy" rating on Merck stock.

FORBES: Merck Wins Battle, Faces War

Robert Hazlett, an analyst at SunTrust Robinson Humphrey, said in a note to investors this morning that the news could mean that the drug, SU-11248, could be submitted to the U.S. Food and Drug Administration in the first quarter of this year, and that it could be approved by the end of 2005.

FORBES: Pfizer Cancer Pill Proves Effective

"This is a very, very important drug for them, " says Robert Hazlett , a pharmaceuticals analyst at SunTrust Robinson Humphrey .

FORBES: Magazine Article

"I think this is the quarter where they've finally begun to right the ship, " says Robert Hazlett, a pharmaceuticals analyst at SunTrust Robinson Humphrey.

FORBES: Bristol Searches For An Even Keel